A Focus on Structural Brain Imaging in the Alzheimer’s Disease Neuroimaging Initiative
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
In recent years, there has been a wealth of laboratories and consortia that use neuroimaging to evaluate the risk for and progression of Alzheimer's disease (AD). One such consortium is the Alzheimer's Disease Neuroimaging Initiative (ADNI) - a longitudinal, multi-center study that evaluates a range of biomarkers for use in AD diagnoses, predicting patient outcomes, and for clinical trials. These biomarkers include brain metrics derived from magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and metrics derived from blood and cerebrospinal fluid (CSF). Here we focus on ADNI studies, published between 2011 and March 2013, for which structural MRI was a major outcome measure. Our main goal here was to review key papers offering insights into AD progression, and the relationships of structural MRI measures to cognition and to other biomarkers in AD. In the Supplemental Materials, we also discuss genetic and environmental risk factors for AD, and exciting new analysis tools for the efficient evaluation of large scale structural MRI data sets such as ADNI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 3×
“progression from a group outside of the ADNI found that in patients with autosomal dominantly inherited forms of earlyonset AD, CSF tau changes and hippocampal atrophy occurred before FDG-PET metabolism changes and changes in episodic memory (32).”
InfluentialHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 3×
“APOE4-positive controls have greater detectable brain amyloid (44) and lower CSF Aβ (52,53) than APOE4 noncarriers.”
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“However, there are already differences in FDG-PET between APOE4-positive and APOE4negative subjects in their 20s and 30s (29), whereas APOE4 is not associated with brain amyloid positivity (measured with florbetapir) until approximately age 56 (30).”
Cited by
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Mak, E., Gabel, S., Mirette, H., Su, L., Williams, G. B., Waldman, A., Wells, K., Ritchie, K., Ritchie, C., & O’Brien, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.10.001 · Cited by 71
“…loss, cortical thinning, or white matter microstructural changes have contributed to the characterisation of diseaserelated changes in neurodegenerative conditions, such as AD (Braskie and Thompson, 2014), dementia with Lewy bodies (Mak et al., 2014a), and Parkinson‟s disease (Mak et al., 2015a).”
Metadata
- Authors
- Braskie, M. N., & Thompson, P. M.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 75
- Issue
- 7
- Pages
- 527-533
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2016777699
- Cited by
- 51
- References
- 25
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Focus on Structural Brain Imaging in the Alzheimer’s Disease Neuroimaging Initiative. https://app.cochat.ai/papers/10.1016/j.biopsych.2013.11.020
- The paper
- Braskie, M. N., & Thompson, P. M. (2014). A Focus on Structural Brain Imaging in the Alzheimer’s Disease Neuroimaging Initiative. Biological Psychiatry. https://doi.org/10.1016/j.biopsych.2013.11.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.